RT Journal Article
T1 Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine.
T2 Incidencia de la COVID-19 en pacientes en tratamiento crónico con hidroxicloroquina.
A1 Tejada Cifuentes, Francisco
A1 Lloret Callejo, Ángeles
A1 Tirado Peláez, María José
A1 Rubio Pulido, Olga
A1 Ruiz-Morote Aragón, Marta
A1 Fernández Urrusuno, Rocío
A1 Muñoz Carreras, María Isabel
A1 Méndez Esteban, María Isabel
A1 Maestre Sánchez, Victoria
A1 García Bonilla, Antonio
A1 Paredero Dominguez, José Manuel
A1 Arroyo Pineda, Virginia
A1 Marco Tejón, Esther
A1 Romero Candel, Gregorio
A1 Fernández Marchante, Ana Isabel
A1 Marco Del Rio, José
A1 Ortiz Martín, Teresa
A1 López Sánchez, Piedad
K1 COVID-19
K1 Coronavirus
K1 Hidroxicloroquina
K1 Hydroxychloroquine
K1 Incidence
K1 Incidencia
K1 Tratamiento
K1 Treatment
AB To analyze the incidence of Covid-19 in patients who are chronic users of hydroxychloroquine. Cross-sectional retrospective observational multicenter study in health areas and districts from Castilla La-Mancha and Andalucia. Of the 4451 participants included in the first recruitment, 3817 with valid data were selected. The main variable of the study is the presence or absence of Covid-19 infection by clinical, serological or polymerase chain reaction diagnosis. Sociodemographic and clinical variables and treatment and concomitant comorbidities were recorded. 169 (4,45%) patients had Covid-19 infection, of which 12 (7.1%) died and 32 (18.9%) required hospital admission. Previous respiratory pathology was related to Covid-19 infection (P There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19.
YR 2020
FD 2020-11-06
LK http://hdl.handle.net/10668/16780
UL http://hdl.handle.net/10668/16780
LA en
LA es
DS RISalud
RD Apr 5, 2025